Is 5mg Mounjaro effective, and what should you expect at this dose?

What SURMOUNT-1 actually showed at the 5mg dose

The SURMOUNT-1 trial is the foundational evidence behind Mounjaro's UK weight-management licence. Over 72 weeks, 2,539 adults with obesity (BMI ≥30, or ≥27 with at least one weight-related condition) were randomised to 5mg, 10mg or 15mg tirzepatide, or placebo, alongside a structured lifestyle programme. At 5mg, participants lost around 15% of their body weight on average, roughly 15–16 kg for someone starting at 100 kg. That figure is not a ceiling; individual results in the trial ranged higher and lower, shaped by factors like starting weight, adherence to dietary changes, and individual metabolic response.

Crucially, the trial design matters. Every participant also followed a reduced-calorie diet and increased their activity levels, guided by lifestyle counselling throughout. The medicine works alongside those changes, not instead of them. The NICE technology appraisal of tirzepatide (TA1026) noted the trial data when recommending the medicine for NHS use, and NICE's recommendation itself requires that treatment is accompanied by dietary support and physical activity advice. So when a patient asks whether 5mg is effective, the honest answer is: yes, substantially, with the lifestyle work in place.

It is also worth knowing that effectiveness tends to build. Most people do not lose the majority of their weight in the first few weeks on 5mg; the appetite-suppressing effects deepen as the medicine reaches steady state, and weight loss typically accelerates over months rather than days. If your progress feels slow in week five or six, that is not a sign the dose has failed.

Why 5mg is more than just a stepping stone

There is a common assumption that 5mg is simply a rung you climb past as quickly as possible. That is not quite right. The 2.5mg starter pen exists to let your body adjust to tirzepatide's gastrointestinal effects, nausea, bloating, and changes in appetite can be pronounced if you start at a higher dose. Moving to 5mg after four weeks is the point where the medicine begins working in earnest. For some people, 5mg turns out to be the dose they stay on.

Prescribers will consider keeping a patient at 5mg if weight loss is progressing steadily, side effects are minimal, and there is no clinical reason to increase. Titration to higher doses is not automatic or mandatory. You can explore what guides these decisions in more detail on our page about which Mounjaro dose is most effective overall, that page covers how prescribers weigh the evidence across the full 2.5–15mg range.

If you are wondering how the 5mg pen compares specifically to the 2.5mg experience (and many people are, because the two can feel quite different) our page on whether 2.5mg Mounjaro is effective covers the distinction clearly. The short version: 2.5mg is about getting used to the medicine; 5mg is where treatment begins.

Side effects and tolerability at 5mg

Understanding effectiveness means understanding the full picture, including what to expect on the way. At 5mg, GI side effects (nausea, loose stools, reduced appetite beyond what's comfortable, and occasional indigestion) are common and most noticeable in the days after the dose increase from 2.5mg. For most people they settle within one to two weeks. They are not a sign that the medicine is harming you; they reflect tirzepatide's mechanism acting on gut-hormone receptors.

The NHS's patient information for tirzepatide sets out the side-effect profile in full, and it is worth reading before you start: NHS guidance on tirzepatide. Our own guide to 5mg Mounjaro side effects covers what people most commonly notice at this specific dose and what can help. If you experience severe, persistent stomach pain that radiates to the back, seek medical attention promptly, this is one of the warning signs the MHRA has highlighted in relation to GLP-1 medicines.

If you are thinking about what 5mg involves in practice (the pen format, how it is used, storage) our Mounjaro 5mg overview covers the practical detail, while the Mounjaro treatment page gives the broader context.

Who reaches 5mg, and what comes next

We hear this question a lot from people who are mid-titration and genuinely uncertain whether what they are experiencing at 5mg is working. That uncertainty is completely normal. Weight loss on tirzepatide is not linear, and comparing your early weeks against clinical-trial averages is not always reassuring when the scale has barely moved yet.

In terms of who is eligible to receive Mounjaro at all: the licensed criteria require a BMI of 30 or above, or 27 and above if you have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. A prescriber assesses your whole picture (not just your BMI) before any prescription is issued or any dose confirmed. For a fuller breakdown of how eligibility works and what the most effective Mounjaro dose tends to be across different patient profiles, both linked pages go into more depth.

If you are considering starting treatment and want a clinical assessment, a free consultation with one of our prescribers is the right next step. A real clinician reviews your answers the same day, your case lands on a prescriber's desk, not in a software queue.